Alexza Pharmaceuticals, Inc. (ALXA) Posts Q2 EPS Loss of $0.13

Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) reported Q2 EPS of ($0.13), $0.02 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $1.26 million versus the consensus estimate of $430 thousand.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business
• Evogene (EVGN) Tops Q2 EPS by 15c